Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DAVITA INC.DVA · Entity 3482 | Director | August 15, 2026 | August 18, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director · President & CEO | August 11, 2026 | August 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres-Global Human Health | November 01, 2018 | November 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DAVITA INC.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,970 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 278 · Balance 5,970 |
LABCORP HOLDINGS INC.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,565 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 4,669 · Balance 102,565 F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Merck & Co., Inc.
Report date November 01, 2018 · Filed November 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-11-01 · Exercise / conversion · Acquired 277,879 · Balance 277,879 Row 2 · 2018-11-01 · Sale · Disposed 132,744 · Balance 145,135 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2018-11-01 · Sale · Disposed 145,135 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.29 · Expires 2022-05-01 | Direct | 0 |
Reported balance
After 2018-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-01 · Exercise / conversion · Disposed 277,879 · Balance 0 F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 55,405.9747 |
Reported balance
Holding disclosure · report date 2018-11-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 55,405.9747 F4: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 22:10 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 278 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-26-000122 · wk-form4_1787091036.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,970 Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:31 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 4,669 | $320.37 | $1,495,807.53 |
DisclosureSEC source: 0000920148-26-000177 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,565 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:11 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-26-000079 · wk-form4_1779135078.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,692 Read SEC document |
| May 11, 2026 Filed May 13, 2026 13:30 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 5,903 | $254.50 | $1,502,313.50 |
DisclosureSEC source: 0000920148-26-000140 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,234 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:58 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 26,106 | $268.38 | $7,006,328.28 |
DisclosureSEC source: 0000920148-26-000126 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,137 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:58 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 58,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000126 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,243 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:09 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 332 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-26-000037 · wk-form4_1773778153.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,442 Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 13:57 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 8,705 | $279.96 | $2,437,047.45 |
DisclosureSEC source: 0000920148-26-000114 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,773 Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000086 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,214 Underlying: Common Stock · 3,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,521 | $289.89 | $440,922.69 |
DisclosureSEC source: 0000920148-26-000086 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,478 F3 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000086 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 18:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 5,273 | $284.38 | $1,499,535.74 |
DisclosureSEC source: 0000920148-26-000086 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,343 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 20:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 10,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000070 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,870 Underlying: Common Stock · 10,440 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 20:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 31,700 | $0.00 Strike: $284.50 | $0.00 |
DisclosureSEC source: 0000920148-26-000070 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,700 Underlying: Common Stock · 31,700 shares Expires 2036-02-09 F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,352 | $274.01 | $370,461.52 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,616 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,249 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,430 Underlying: Common Stock · 3,249 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 4,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,679 Underlying: Common Stock · 4,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,315 | $277.20 | $364,518.00 |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,719 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 20:13 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 4,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000031 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| November 15, 2025 Filed Nov 17, 2025 23:47 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 411 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-25-000179 · wk-form4_1763423225.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,110 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 13:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 5,745 | $262.75 | $1,509,498.75 |
DisclosureSEC source: 0000920148-25-000108 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,574 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:25 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 369 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-25-000151 · wk-form4_1755638727.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,699 Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 16:29 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 5,643 | $266.78 | $1,505,439.54 |
DisclosureSEC source: 0001127602-25-020382 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,319 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2025 Filed May 17, 2025 01:13 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 348 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-25-000097 · wk-form4_1747444427.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,330 Read SEC document |
| May 12, 2025 Filed May 13, 2025 14:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 6,105 | $248.73 | $1,518,496.65 |
DisclosureSEC source: 0001127602-25-014013 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,962 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 14:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 13,584 | $231.67 | $3,147,005.28 |
DisclosureSEC source: 0001127602-25-010619 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,067 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 14:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 30,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-010619 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,651 F1 · kind: Shares acquired on March 27, 2025, pursuant to a performance award granted on February 11, 2022, relating to performance during the three-year period ended December 31, 2024. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 23:40 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 349 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-25-000055 · wk-form4_1742341227.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,982 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,139 Underlying: Common Stock · 2,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F8 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 11, 2023 and are now fully vested. F7 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 10,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,102 Underlying: Common Stock · 10,970 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F6 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2026. F7 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 33,100 | $0.00 Strike: $245.14 | $0.00 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,100 Underlying: Common Stock · 33,100 shares Expires 2035-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,226 | $245.14 | $300,541.64 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,182 F3 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,963 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 16:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 6,121 | $244.62 | $1,497,319.02 |
DisclosureSEC source: 0001127602-25-004543 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,445 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · derivative · entry 6 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,132 Underlying: Common Stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Common Inc. Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,345 | $246.27 | $331,233.15 |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · nonDerivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,566 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · nonDerivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Common Inc. Stock. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 4,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,382 Underlying: Common Stock · 4,460 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Common Inc. Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,240 | $247.74 | $307,197.60 |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,661 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 14:12 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 4,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003714 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Common Inc. Stock. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:24 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-24-000191 · wk-form4_1732051449.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,633 Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 13:16 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 6,189 | $243.47 | $1,506,835.83 |
DisclosureSEC source: 0001127602-24-027132 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,441 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 22:24 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 333 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-24-000147 · wk-form4_1724106249.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,321 Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:31 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 363 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-24-000112 · wk-form4_1715981475.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,988 Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:23 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 72,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-24-000022 · primary_doc.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,842 Underlying: Common Stock · 72,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024. F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024. F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:23 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 31,799 | $216.57 | $6,886,709.43 |
DisclosureSEC source: 0000920148-24-000022 · primary_doc.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,630 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:23 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 72,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-24-000022 · primary_doc.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:29 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 366 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-24-000062 · wk-form4_1710894546.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 17:17 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,231 | $227.45 | $279,990.95 |
DisclosureSEC source: 0001127602-24-004643 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,994 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.